BridgeBio Pharma (BBIO) Intangibles (2018 - 2026)

BridgeBio Pharma has reported Intangibles for 8 years, with the latest figure at $27.4 million in Q1 2026.

• Quarterly Intangibles fell 1.59% year-over-year to $27.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.4 million (down 1.59% YoY) and the FY2025 annual result came in at $28.1 million, up 17.35% from the prior year.
• Intangibles retreated to $27.4 million in Q1 2026 per BBIO's latest filing, from $28.1 million in the prior quarter.
• Over five years, Intangibles peaked at $30.5 million in Q1 2022 and troughed at $23.9 million in Q4 2024.
• A 5-year average of $27.5 million and a median of $27.8 million in 2025 frame the typical range for Intangibles.
• The widest YoY moves for Intangibles: up 91.41% in 2022, down 36.56% in 2022.
• Over 5 years, Intangibles stood at $28.7 million in 2022, then decreased by 8.33% to $26.3 million in 2023, then fell by 9.09% to $23.9 million in 2024, then grew by 17.35% to $28.1 million in 2025, then decreased by 2.56% to $27.4 million in 2026.
• According to Business Quant data, Intangibles over the past three periods registered $27.4 million, $28.1 million, and $28.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.